ReviewInternational journal of molecular sciences2015
Chemopreventive potential of green tea catechins in hepatocellular carcinoma.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Liver Disease and Plant-Derived Phytoconstituents: From Ethnopharmacology to Modern Medicine.Phytotherapy research : PTR · 2026Review
- Carob pod aqueous extract potentiates cisplatin efficacy and reduces toxicity in experimental hepatocellular carcinoma via mitochondrial and inflammatory pathway modulation.Bioresources and bioprocessing · 2026Article
- Comprehensive pan-cancer analysis of USP35 and validation of its role in gastric cancer.Human genomics · 2025Article
- Green Tea Components: In Vitro and In Vivo Evidence for Their Anticancer Potential in Colon Cancer.Cancers · 2025Review
- The interplay of exercise and green tea: a new road in cancer therapy.Cancer cell international · 2025Review
- Toxicity Potential of Nutraceuticals.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Role of Dietary Ingredients and Herbs in the Prevention of Non-Communicable Chronic Liver Disease.Nutrients · 2024Review
- Evidence-based herbal treatments in liver diseases.Hepatology forum · 2024Review
- Tea consumption and risk of lung diseases: a two‑sample Mendelian randomization study.BMC pulmonary medicine · 2023Article
- Cumulative consumption of tea is associated with lower risk of liver cancer: Updated results from the Shanghai Women's Health Study.International journal of cancer · 2023Article
- Anticancer Therapeutic Effects of Green Tea Catechins (GTCs) When Integrated with Antioxidant Natural Components.Molecules (Basel, Switzerland) · 2023Review
- Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.World journal of gastroenterology · 2023Review
- Unveiling the Antioxidant, Clinical Enzyme Inhibitory Properties and Cytotoxic Potential ofMolecules (Basel, Switzerland) · 2023Article
- Bibliometric and visual analysis in the field of tea in cancer from 2013 to 2023.Frontiers in oncology · 2023Article
- Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats.F1000Research · 2022Article
- Are Nutraceuticals Beneficial in Chronic Kidney Disease?Pharmaceutics · 2021Review
- The counteracting effects of (-)-Epigallocatechin-3-Gallate on the immobilization stress-induced adverse reactions in rat pancreas.Cell stress & chaperones · 2021Article
- Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment.European journal of integrative medicine · 2020Review
- Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Chlorogenic Acid Decreases Malignant Characteristics of Hepatocellular Carcinoma Cells by Inhibiting DNMT1 Expression.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), which is a common malignancy worldwide, usually develops in a cirrhotic liver due to hepatitis virus infection. Metabolic syndrome, which is frequently complicated by obesity and diabetes mellitus, is also a critical risk factor for liver carcinogenesis. Green tea catechins (GTCs) may possess potent anticancer and chemopreventive properties for a number of different malignancies, including liver cancer. Antioxidant and anti-inflammatory activities are key mechanisms through which GTCs prevent the development of neoplasms, and they also exert cancer chemopreventive effects by modulating several signaling transduction and metabolic pathways. Furthermore, GTCs are considered to be useful for the prevention of obesity- and metabolic syndrome-related carcinogenesis by improving metabolic disorders. Several interventional trials in humans have shown that GTCs may ameliorate metabolic abnormalities and prevent the development of precancerous lesions. The purpose of this article is to review the key mechanisms by which GTCs exert chemopreventive effects in liver carcinogenesis, focusing especially on their ability to inhibit receptor tyrosine kinases and improve metabolic abnormalities. We also review the evidence for GTCs acting to prevent metabolic syndrome-associated liver carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.